Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...

Which mineralocorticoid receptor antagonists (MRAs; ie, steroidal, nonsteroidal) are currently indicated or used for treating heart failure with midrange ejection fraction (HFmrEF) and HF failure ...

Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations. Emerging treatments could reduce hospitalization rates and ...

Medically reviewed by Jeffrey S. Lander, MDMedically reviewed by Jeffrey S. Lander, MD Congestive heart failure (CHF), also ...

The trial was done in adults with obesity and heart failure with preserved ejection fraction (HFpEF). The data, posted online on August 1, has not yet been published in a peer-reviewed journal.

Translational and clinically relevant physiological and pathophysiological concepts as they apply to nursing practice are examined. Selected signs/symptoms are considered in terms of physiological ...

RA patients are particularly susceptible to a type of heart failure with preserved ejection fraction (HFpEF), which is accompanied by diastolic dysfunction ... My research aims are to understand the ...

Semaglutide can improve HF outcomes by impacting pathophysiology of HFpEF patients Semaglutide (2.4mg) improved obesity-related HF symptoms in people with inflammation and both with and without ...

Serum magnesium plays a crucial role in the pathophysiology of sepsis. Elevated serum magnesium levels are associated with poor outcomes, potentially through mechanisms such as exacerbating ...